Dose-escalation study demonstrates manageable myelosuppression and antitumor activity for vinblastine in neoplastic disease, highlighting viable dosing protocols.
ONE OF THE most important advances in clinical cancer chemotherapy in recent years has been the demonstration that products of the periwinkle plantVinca roseaLinn. have antitumor activity in patients with neoplastic disease.1Vinblastine has been effective in patients with Hodgkin's disease and lymphosarcoma.2,3There is also evidence for some degree of antitumor activity in a variety of solid tumors, particularly carcinoma of the breast, but the extent of this effect is not clear.1The Eastern Cooperative Group in Solid Tumor Chemotherapy undertook preliminary studies of vinblastine in 1961. Dose response studies indicated that for the majority of patients 0.3 mg/kg was well tolerated, producing in most of the patients mild to moderate, reversible myelosuppression.3Because occasionally a patient had myelosuppression with smaller doses, it was proposed that the doses employed in the therapeutic trial start at 0.1 mg/kg/week and be increased by 0.1 mg/kg/week to a maximum of
No takes yet. Share an insight, caveat, or question.
A 1965 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: